AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) investors are getting enthusiastic again after the biotech firm’s Phase 3 IAP312 clinical trial of Zalviso, approved in the …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) investors are quaking today in the upshot of earnings not so far off the mark from second quarter expectations. …
The next key catalyst for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is Dsuvia’s Prescription Drug User Fee Act (PDUFA) on October 12, 2017 for the …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) reported key results from the Phase 3 IAP312 study of ZALVISO® (sufentanil sublingual tablet system), an investigational product candidate …
Will the FDA grant its key blessing to AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) come October 12th for its lead acute pain reliever drug candidate, …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced the appointment of Raffi Asadorian as chief financial officer, effective August 16, 2017. Mr.
In a research report issued Friday, Jefferies analyst Matthew Andrews assumed coverage on shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), with a Buy rating and a $7.00 price …
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) announced that it has submitted a New Drug Application (NDA) under section 505(b)(2) with the U.S.
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) announced an update to the agenda for its December 1, 2016 Analyst & Investor Event. Dr.
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced an upcoming presentation at the 15th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and …
